OTC:VXRT
Vaxart, Inc.
A clinical-stage biotech firm developing oral vaccines for autoimmune conditions, showing strong recent revenue growth despite operating losses.
Key Metrics
Investment Thesis
Bull Case
Investors might consider VXRT due to the potential for a paradigm shift in autoimmune treatment through its needle-free oral vaccine platform. The recent surge in revenue and strategic partnerships indicate growing industry confidence in the company's technology pipeline. If clinical trials succeed, the value of the current marketable securities ($26.5M) could be amplified significantly upon product commercialization.
Bear Case
The stock is vulnerable to dilution from frequent equity financing needs given the substantial retained earnings deficit of -$476.5M and negative cash flow from operations of -$44.8M. Current liabilities of $90.9M exceed current assets, creating a working capital challenge that limits operational flexibility without immediate capital injection. High operating expenses relative to revenue suggest the company is burning through resources faster than its top line can sustainably support.
About Vaxart, Inc.
Vaxart, Inc. (VXRT) is a clinical-stage biotechnology company developing oral vaccines and therapeutics using its proprietary technology platform. The company primarily serves the immunology market with a focus on treating autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease. Recent financials show a significant revenue jump to $28.7M in 2024, driven by research and development activities totaling $74.2M.
Analysis
Management Discussion
Management has successfully navigated a period of rapid growth, evidenced by the tripling of revenue from $7.4M to $28.7M over the past two years. However, this expansion comes at the cost of deepening losses, with operating expenses reaching $95.0M and a net change in cash of -$9.5M. The significant non-cash adjustments of -$51.0M suggest complex accounting dynamics related to equity-based compensation or asset valuations affecting reported profitability.
Industry Overview
The biotechnology and pharmaceutical industry is characterized by high R&D costs and significant regulatory hurdles before products can reach market approval. Companies in this space often operate at a loss for years while building their pipelines, relying on venture capital or public markets for funding. Success depends heavily on the ability to secure patents and navigate complex clinical trial landscapes to bring novel therapies to patients.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $107.0K | $7.4M | $28.7M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $107.0K | $7.4M | $28.7M |
| Operating Expenses | $114.7M | $90.7M | $95.0M |
| Operating Income | $-114.6M | $-83.3M | $-66.3M |
| R&D | $81.1M | $68.1M | $74.2M |
| G&A | $29.4M | $22.6M | $20.8M |
| Stock-Based Comp | $13.6M | $14.1M | $11.5M |
| D&A | $5.8M | $8.6M | $8.8M |
| Depreciation | $2.0M | $3.8M | $3.7M |
| Amortization | $1.3M | $700.0K | $700.0K |
| Other OpEx | $4.3M | $0 | $0 |
| Non-Operating Income | $6.9M | $1.1M | $-395.0K |
| Pre-Tax Income | $-107.7M | $-82.2M | $-66.7M |
| Income Tax | $67.0K | $261.0K | $260.0K |
| Continuing Ops | $-107.8M | $-82.5M | $-66.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-107.8M | $-82.5M | $-66.9M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-107.8M | $-82.5M | $-66.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $99.5M | $45.5M | $68.3M |
| Cash & Equivalents | $44.0M | $34.8M | — |
| Marketable Securities | $49.7M | $5.0M | $26.5M |
| Accounts Receivable | $20.0K | $3.0M | $5.8M |
| Prepaid Expenses | $3.7M | $2.8M | $4.6M |
| Other Current Assets | $2.0M | $0 | $31.4M |
| Long-Term Assets | $54.4M | $46.3M | $98.1M |
| PP&E (Net) | $15.6M | $11.7M | $8.7M |
| Intangibles | $5.0M | $4.3M | $3.6M |
| Goodwill | $4.5M | $4.5M | $4.5M |
| Operating Leases | $25.7M | $24.8M | $20.4M |
| LT Investments | $0 | — | — |
| Other LT Assets | $3.6M | $926.0K | $61.0M |
| Total Assets | $153.8M | $91.8M | $166.4M |
| Current Liabilities | $17.9M | $13.7M | $90.9M |
| Accounts Payable | $5.5M | $1.6M | $7.0M |
| Current Leases | $2.2M | $2.7M | $3.1M |
| Other Current Liab | $2.1M | $3.8M | $69.5M |
| Long-Term Liabilities | $25.3M | $20.3M | $16.6M |
| LT Operating Leases | $19.5M | $17.4M | $14.4M |
| Other LT Liab | $5.9M | $2.9M | $2.1M |
| Total Liabilities | $43.2M | $34.0M | $107.5M |
| Shareholders' Equity | $110.6M | $57.8M | $58.9M |
| Retained Earnings | $-327.1M | $-409.6M | $-476.5M |
| AOCI | $-299.0K | $-1.0K | $4.0K |
| Total L&E | $153.8M | $91.8M | $166.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-107.8M | $-82.5M | $-66.9M |
| Non-Cash Adjustments | $14.2M | $24.0M | $-51.0M |
| Working Capital Changes | $-1.2M | $-12.0M | $73.1M |
| Cash from Operations | $-94.8M | $-70.5M | $-44.8M |
| Capital Expenditures | $9.6M | $1.9M | $554.0K |
| Cash from Investing | $-20.4M | $44.0M | $-21.3M |
| Cash from Financing | $17.5M | $15.2M | $56.6M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-97.7M | $-11.3M | $-9.5M |
| Beginning Cash | $143.7M | $46.0M | $34.8M |
| Ending Cash | $46.0M | $34.8M | $25.2M |
Frequently Asked Questions
How does Vaxart, Inc. make money?
The company's operations are centered around its core technology platform for creating oral vaccines that do not require needles. Revenue streams currently derive from strategic partnerships and licensing agreements rather than direct product sales, as the company is still in clinical development phases. Significant expenditures are directed toward research and development to advance its pipeline candidates through regulatory approval.
What are the main risks for VXRT?
The company faces substantial cash burn risks with net income of -$66.9M, requiring continued reliance on external financing to fund operations. As a pre-revenue clinical-stage biotech, VXRT carries high regulatory and development failure risks common in the industry. The heavy investment in R&D ($74.2M) combined with limited current cash reserves creates liquidity pressures that could impact long-term viability if new funding rounds are not secured.
What is VXRT's competitive advantage?
Vaxart possesses a unique proprietary platform enabling oral vaccine delivery without injections, which significantly improves patient compliance compared to traditional injectable therapies. The company benefits from established collaborations with major pharmaceutical entities that provide funding and accelerate clinical trial progress. Its focus on treating difficult-to-manage autoimmune conditions addresses a large unmet medical need in the therapeutic market.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.